<DOC>
	<DOCNO>NCT02138253</DOCNO>
	<brief_summary>This double-blind , multicenter study involve patient chronic HCV infection liver transplantation ; develop HCV-related liver fibrosis and/or incomplete cirrhosis ; achieve sustain virologic response ( SVR ) follow anti-HCV therapy ; still fibrosis and/or incomplete cirrhosis liver biopsy see treatment IDN-6556 better placebo reverse stop progression damage new liver cause HCV .</brief_summary>
	<brief_title>A Trial IDN-6556 Post Orthotopic Liver Transplant Chronic HCV</brief_title>
	<detailed_description>There data suggest eradication HCV virus , improvement liver fibrosis see post-transplant population . However , amelioration inflammatory activity , deceleration fibrosis progression gradual process course many year . This placebo-controlled study design evaluate effect IDN-6556 , compare placebo , marker apoptosis inflammation , liver histology .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Male female subject minimum adult legal age ( accord local law sign informed consent document ) , able provide write informed consent , able understand willing comply requirement study History orthotopic liver transplantation HCVinduced liver disease Diagnosis HCV infection ( HCVRNA detectable serum ) liver fibrosis and/or incomplete cirrhosis status post liver transplantation , achieve sustain virologic response ( SVR ) antiviral HCV treatment within 18 month Day 1 Liver fibrosis liver histology read central histopathologist Ishak F2 F6 within three month Day 1 ( Up 15 subject Ishak score F6 enrol ) Willingness utilize two reliable form contraception ( male females childbearing potential ) Screening one month last dose study drug Known infection hepatitis B virus ( HBV ) and/or human immunodeficiency virus ( HIV ) History renal transplant and/or severe renal impairment define eGFR ( estimate glomerular filtration rate ) le 30 mL/min/1.73 m2 Evidence tumor burden &gt; Milan criterion , evidence micro macrovascular invasion explanted liver Hepatocellular carcinoma ( HCC ) entry study Concurrent sirolimus ( rapamycin ) use History presence clinically concern cardiac arrhythmia , prolongation Screening ( pretreatment ) QT QTc interval &gt; 480 millisecond ( msec ) Subjects diagnose suspected systemic lupus erythematosus ( SLE ) and/or rheumatoid arthritis ( RA ) If female : know pregnancy , positive urine serum pregnancy test , lactating/breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>liver transplant</keyword>
	<keyword>hepatitis C</keyword>
	<keyword>liver fibrosis</keyword>
	<keyword>hepatic fibrosis</keyword>
	<keyword>liver cirrhosis</keyword>
	<keyword>hepatic cirrhosis</keyword>
</DOC>